220
Participants
Start Date
September 8, 2025
Primary Completion Date
September 18, 2027
Study Completion Date
September 18, 2027
CS32582 capsule（low dose） or matched placebo
CS32582 capsule（low dose） or matched placebo，4 weeks
CS32582 capsule（high dose） or matched placebo
CS32582 capsule（high dose） or matched placebo，4 weeks
CS32582 capsule（low dose）
CS32582 capsule（low dose），12 weeks
CS32582 capsule（medium dose）
CS32582 capsule（medium dose），12 weeks
CS32582 capsule（high dose）
CS32582 capsule（high dose），12 weeks
NOT_YET_RECRUITING
Beijing Friendship Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Peking University People's Hospital, Beijing
NOT_YET_RECRUITING
Affiliated Hospital of Chengde Medical University, Chengde
RECRUITING
The First Hospital of Hebei Medical University, Shijiazhuang
NOT_YET_RECRUITING
Shiyan People's Hospital, Shiyan
NOT_YET_RECRUITING
Shandong Provincial Hospital for Skin Diseases, Jinan
NOT_YET_RECRUITING
First Hospital of Shanxi Medical University, Taiyuan
NOT_YET_RECRUITING
The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital ), Xi’an
NOT_YET_RECRUITING
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou
NOT_YET_RECRUITING
The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu
NOT_YET_RECRUITING
The First Affliated Hospital of Wenzhou Medical University, Wenzhou
Lead Sponsor
Chipscreen Biosciences, Ltd.
INDUSTRY